ANNX (Annexon) Net Profit

Official company branding of Annexon Biosciences (ANNX)

Annexon, Inc. (ANNX) maintains an environmental policy limited to laboratory controls and office recycling, which allows for the tracking of the current -0.21 metric via the price chart. The company specializes in developing agents to suppress the complement pathway. Looking ahead, the business's financial success will rely on the commercialization of therapies for ophthalmological, neurodegenerative, and autoimmune pathologies currently undergoing clinical trials.

ANNX - annexonbio.com Company Net Income over the range 07/04/2022 - 10/30/2026

Comprehensive metric breakdowns and analytics for Annexon (ANNX)

- stock value and consensus price forecast:
Market Price Annexon Biosciences Inc.|ANNX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Annexon Biosciences Inc.|ANNX - Total Company Value
- book capitalization data:
Equity per Share Annexon|ANNX - Company Book Value|Capitalization to Book Value Ratio annexonbio.com|ANNX - Company Total Assets
- debt and liquidity details:
Debt to Capital Annexon, Inc.|ANNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio Annexon Biosciences|ANNX - Company Debts|Debts to Book Value Annexon Biosciences Inc.|ANNX - Company Long-Term Debt|Company Short-Term Indebtedness Annexon|Intermediate Coverage Ratio annexonbio.com
- earnings and market ratios statistics:
ANNX - Net Profit
Basic company analysis:ANNX Annexon Biosciences Inc.
Signature product of Annexon Biosciences Inc.

The reliability of equity assets is determined by the stability of cash flows. This indicator measures the daily difference between total income and expenses, neutralizing gaps between quarterly reports. For Annexon, Inc. (ANNX) and its extensive R&D expenditures on complement therapy, this metric reflects the efficiency of its capital burn. By analyzing the company's net profit, an investor identifies sustainable price corridors. The upper bound of this net profit for Annexon, Inc. (ANNX) signals the issuer's strength but warns of a potential correction.

Main competitors

Company Net Income Biogen Idec (BIIB)|NBIX (Neurocrine Biosciences) - Net Profit|Net Profit regencellbioscience.com|Company Net Income Axsome Therapeutics, Inc. (AXSM)|ACADIA Pharma - Company Profit|Company Net Income Xenon Pharmaceuticals Inc XENE|VKTX: Company Profit|Supernus Pharmaceuticals - Net Profit|Company Net Income catalystpharma.com|DNLI (Denali Therapeutics Inc.) - Net Income|Company Profit HRMY|Company Net Income Biohaven Pharmaceutical|Company Net Income Amylyx Corp AMLX|Company Net Income Trevi Therapeutics (TRVI)|praxismedicines.com - Company Profit|Anavex Life Sciences Corp. - Net Income|Final Profit CBLL|Prothena Biosciences - Net Profit|Net Financial Result Alector, Inc. ALEC|omeros.com (OMER) - Company Net Income|Company Profit NGNE|ACIU (AC Immune SA) - Net Profit|Net Income Voyager Therapeutics Inc (VYGR)|Net Income NMRA (Neumora Therapeutics Inc)|Net Financial Result Scilex Holding Company, Inc.|Net Profit TVGN (Tevogen Bio Holdings)|Net Profit Alpha Cognition Inc ACOG|CGTX - Company Net Income|IKT (Inhibikase Therapeutics Inc) - Company Profit|Cassava (SAVA) - Company Net Income|Company Profit ASRT|Net Income COYA|Company Profit VTGN (VistaGen Therapeutics Inc)|Company Net Income Ovid Therapeutics Inc. (OVID)|Acumen Pharmaceuticals Inc. - Company Profit|Net Profit CRVO (CervoMed Inc)|Alterity Therapeutics Ltd. (ATHE) - Company Net Income|CLNN: Net Income|PEPG - Net Profit|Jupiter Neurosciences Inc (JUNS) - Company Net Income|Relmada Therapeutics Inc - Final Profit|Company Net Income Annovis Bio Corp|Company Net Income Grace Tx GRCE|Net Profit AIFF|Net Profit anewmeds.com (KLTO)|Company Net Income NeuroSense Therapeutics Ltd. NRSN|RVPH: Company Profit|MTVA - Company Net Income|NRXS (NeurAxis Inc) - Company Profit|HSDT: Net Profit|Company Net Income Passage Bio (PASG)|Net Income NEUP|Company Profit NERV (Minerva Neurosciences Inc)|Company Net Income Athira (ATHA)|ADXN - Company Net Income|Company Net Income Alzamend Neuro ALZN|CYCN: Company Profit|PTIX: Net Income|Final Profit KTTA (Pasithea Therapeutics)|CRGT: Net Profit|ATXI - Net Financial Result|Company Net Income Brainstorm Cell|Company Profit CARA (caratherapeutics.com)|Net Profit CHRO|Net Income eliemtx.com ELYM|Intra-Cellular Therapies, Inc. - Net Income|Net Financial Result Longboard (LBPH)|Marinus Pharmaceuticals - Net Profit|NKGN - Net Profit|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|Company Profit SAGE|Company Net Income Neurotrope|Company Profit TRVN (Trevena Inc)|Net Income VIGL (Vigil Neuroscience)|Anew Medical Inc. - Company Profit|Company Net Income Cerevel Therapeutics, Inc. CERE